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A B S T R A C T
Dermatomyositis is a rare disease characterised by inflamatory muscle affection and characteristic cutaneous
changes. When occuring in a patient with cancer, dermatomyositis may indicate recurrence or progression and poor out-
come. Herein, the treatment of metastatic breast cancer, metastatic pattern, characteristics of long-term survivors, and
link between dermatomyositis and breast cancer are discussed and the literature reviewed. We report a 57-year old female
patient with metastatic bilateral breast cancer whose ovarian and peritoneal relapse after long-term remission was dis-
closed by occurence of paraneoplastic dermatomyositis. The patient previously had a 15-year long disease free-period af-
ter primary treatment for breast cancer before onset of pulmonary dissemination. Following antracycline-based chemo-
therapy, the complete remission lasting another 15 years was accomplished. Dermatomyositis had been resolved upon
induction of second-line taxane-based chemotherapy. After completion of six cycles of gemcitabine and paclitaxel chemo-
therapy, check-up revealed further progression. The patient subsequently underwent six cycles of third-line CAP chemo-
therapy (cyclofosfamide, doxorubicine, cisplatin) but disease progressed and oral capecitabine chemotherapy was initi-
ated. The patient received four cycles of capecitabine followed by further vast progression and finally expired following
massive pulmonary embolism. Our case stresses the need of thorough staging and check-up when dermatomyositis arises
in patients with breast cancer, regardless of previous stable long-term complete remission. Furthermore, we believe that
treatment with curative intent in young patients with metastatic breast cancer, who have good performance statuses and
no comorbidities is required, because it is more likely to produce long-term complete remission. However, following dis-
ease relapse a poor outcome can be expected.
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Introduction
The exact nature of the relationship between derma-
tomyositis and malignant disease has not been entirely
clarified despite numerous studies dedicated to the sub-
ject1. Tumor types that are likely to be associated with
the occurrence of dermatomyositis are ovarian, colo-
rectal, breast and lung cancer2,3.
Dermatomyositis can occur prior or simultaneously
with the diagnosis of a malignant tumor, but can also be
diagnosed in patients after appearance of malignant dis-
ease. The severe course of disease is more frequently ob-
served in patients with simultaneous occurrence of der-
matomyositis and cancer4.
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Approximately 30% of breast cancer patients develop
local recurrence or metastatic disease, mainly in the first
five years with the peak of recurrence rate in the first
two years upon completion of the primary treatment. Af-
ter five years, the annual rates of recurrence rapidly de-
crease, but due to the fact that small risks still persist,
some patients can develop recurrence after a long time
period, sometimes even a few decades after the initial
treatment5. Cases of patients with long-term remission
after treatment of metastatic disease are described, but
the factors suggesting better outcome remain unclear.
Herein a report of the course of disease in a 57-year
old breast cancer patient is presented, with emphasis on
simultaneous occurrence of peritoneal dissemination of
primary disease and dermatomyositis, which took place
almost 30 years after the initial treatment and after
15-years of complete remission. In this patient derma-
tomyositis was a paraneoplastic manifestation of ad-
vanced breast cancer. The modalities of the treatment of
metastatic breast cancer were discussed, as well as capa-
bilities and outcome in this rare case of extensive dissem-
ination after a long time period. This case stresses the
possibility of dermatomiositis being the first symptom of
breast cancer recurrence or progression which then ne-
cessitates stage reevaluation and therapy.
Case Report
Twenty seven year old Caucasian female underwent
right breast mastectomy with axillar dissection in 1980
and in 1984 left breast mastectomy with axillary dissec-
tion. In both cases early breast cancer was diagnosed,
and pathology was ductal invasive carcinoma. After each
operation, postoperative radiation therapy to the chest
wall with tumor dose of 45 Gy with 2,25 Gy fraction was
applied.
Lung dissemination was detected by chest X-ray, in
1995, and consequently, the patient received the first line
of chemotherapy with 6 cycles of CAF regimen (cyclo-
phosphamide, doxorubicin, 5 -fluorouracil). The therapy
resulted in the complete regression of pulmonary meta-
stases, with no evidence of disease on radiological imag-
ing. Within the follow up period of fifteen years, no sign
of disease recurrence was observed on regularly attended
follow up.
In 2008, the patient underwent resection of right kid-
ney due to localised kidney tumour, which was detected
on regular abdominal ultrasound. Pathology report re-
vealed T1NxM0 kidney adenocarcinoma. There were no
signs of recurrence nor dissemination at the time of the
surgery or during the entire subsequent follow up period.
In February 2010, the patient consulted a dermatolo-
gist due to eyelid edema and erythematous changes on
exposed parts of the skin with proximal muscle weakness
(Figure 1). The level of creatine kinase (CK), and electro-
myography (EMG) report were normal, but deltoid mus-
cle biopsy revealed inflammatory myopathy. After con-
sulting the clinical immunologist, diagnosis of paraneo-
plastic dermatomyositis was reached.
Patient was not given steroid pulse therapy due to the
inactivity of disease and normal findings of CK and
EMG. Simultaneously with the occurrence of derma-
tomyositis, the tumor in projection of the right ovary and
multiple nodules in the peritoneum suspicious for metas-
tasis were detected on abdominal ultrasound. Levels of
tumor markers were considerably elevated: CA 15–3 was
240,2 U/mL and CA-125 was 3472 U/mL. Explorative
laparatomy was performed. Extensive dissemination en-
compassing ovaries, omentum and peritoneum was found
and bilateral adnexectomy and omentectomy were per-
formed. Regression of cutaneous changes immediately
followed.
Pathology report based on morphology and immu-
nohistochemical profile of resected adnexa, omentum
and peritoneum, strongly suggested the dissemination of
breast cancer (immunohistochemical analysis revealed
strong positive reaction for estrogen receptor, positive re-
action for epithelial membrane antigen (EMA) and cyto-
keratin 7 (CK7), while the reaction for progesterone re-
ceptors, vimentin, CD 10, pan-CK and HER2 was nega-
tive).
A second-line of breast cancer chemotherapy, six cy-
cles of paclitaxel and gemcitabine, were applied. Conse-
quently, tumor markers levels significantly decreased
(CA 15-3 from 199,4 U/mL to 97,6 U/mL and CA 125
from 3335 U/mL to 1346 U/mL). Clinical status improved
and cutaneous changes withdrew.
As a part of follow up, computed tomography (CT) of
the abdomen and pelvis was performed in July and Octo-
ber 2010. The first CT showed stable disease while the
second one revealed the disease progression with peri-
toneal carcinosis, multiple omental nodules, and exten-
sive ascites. Tumor markers were again elevated (CA
15-3 was 599,7 U/mL and CA-125 was 15207 U/mL).
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Fig.1. Eyelid edema.
Third-line CAP chemotherapy (cyclophosphamide, do-
xorubicin, and cisplatin) was applied through 6 cycles,
followed by further progression (abundant ascites, large
omental deposites). The patient remained in relatively
good performance status and therapy proceeded with
four cycles of oral chemotherapy with capecitabine, with
no side-effects. Unfortunatelly, the patient experienced
vast progression, general condition deterioration and ex-
pired following massive pulmonary embolism. The pa-
tient died altogether two years after the onset of ovarian
and peritoneal dissemination.
Discussion
The connection between dermatomyositis and malig-
nancy has been widely addressed in medical literature.
Nevertheless, dermatomyositis is mostly diagnosed in
non-cancer patients. Dermatomyositis occuring in pa-
tients with no history of cancer could be a paraneoplastic
feature of underlying malignancy or indicate cancer re-
currence in the case of complete remissions after previ-
ous systemic treatment6. Exact mechanisms behind the
connection of dermatomiositis and cancer are still not
clarified. Clinical course of dermatomyositis regularly
follows the course of coexisting cancer, so after resection
or successful systemic treatment of primary cancer, sym-
ptoms of dermatomyositis mostly subside and likewise,
symptoms reappear in case of tumor relapse or progre-
ssion7.
The patient reported in this case is specific due to sev-
eral reasons. Firstly, the patient was diagnosed with bi-
lateral breast cancer. Secondly, after eleven years of a
complete disease free interval following primary treat-
ment, disease relapsed in form of multiple metastatic
pulmonary nodules occurred. Third, antracycline-based
chemotherapy (CAF) produced a fifteen year-long remis-
sion. Fourth, the patient developed a second primary kid-
ney cancer. Fifth, dermatomyositis revealed disease re-
currence in the form of multiple metastatic lesions in
both ovaries and peritoneum, histologically proven to be
a spread of primary breast cancer. Sixth, there was no el-
evation of CK or impairment of EMG, which is uncom-
mon for paraneoplastic dermatomyositis.
The majority of breast cancer recurrences occur in
the first 5 years after primary therapy and in that subset
most recurrences happen in first two years after surgery.
After the first 5 years, the percentage of recurrence
slowly decreases for the next 12 years. Recurrence can
occur even ten years after primary treatment but that is
very rare5. In our patient, cancer recurred eleven years
upon completion of primary treatment, which can be
considered as exceptional.
The course of dermatomyositis is often identical to
those of primary breast cancer. In a report by Osako, CK
as marker of dermatomyositis activity was elevated dur-
ing cancer diagnosis, droped after primary resection and
increased in parallel with the development and progres-
sion of distant metastases8. In our case, the CK level was
normal probably because there was no significant muscle
destruction seen on biopsy and in our patient dermato-
myositis was without corresponding laboratory indicators
and the only sign of disease were skin changes and weak-
ness of proximal musculature. Nevertheless, in our pa-
tient dermatomyositis indicated breast cancer recurren-
ce in a form of peritoneal and ovarian metastases and
after the patient underwent surgery, symptoms subsided.
There are reports that in patients with dermatomyositis
associated with breast cancer, check-up of metastatic
spread or new ovarian cancer is necessary9. In our case,
simultaneusly with onset of dermatomyositis, immediate
patient check-up for distant recurrence was undertaken
which revealed ovarian and peritoneal recurrence. This
is in accordance with reports in the literature, where
flare-up of dermatomyositis is often a sign of breast can-
cer recurrence10.
Median survival for patients with metastatic breast
cancer ranges between 2 and 4 years, however, a minor-
ity of patients survive longer than 3 to 5 years. Some pa-
tients who achieve a complete remission after chemo-
therapy remain in this state for prolonged periods of
time, even beyond 20 years11–13. We analysed two reports
which dealt with characterization of complete respond-
ers to chemotherapy for metastatic breast cancer and en-
compassed longer follow-up data than in other trials
(even 15 years). Analysis indicated that 20% of women
with metastatic breast cancer who have achieved a com-
plete clinical remission were alive and disease-free at five
years. Anthracycline chemotherapy is linked with a lon-
ger disease-free interval after the complete response
along with longer survival14. Likewise, Falkson et al.
found that premenopausal women with metastatic bre-
ast cancer, with a good performance status or with estro-
gen-receptor positive tumors, who were treated with
ooforectomy plus anthracycline chemotherapy, survived
close to five years15. These long-term survivors, com-
pared to overall complete responders and the total pa-
tient population have some common characteristics: they
are usually young, have excellent performance status,
and have limited metastatic disease. Although this frac-
tion represents a small subgroup of patients (between 1%
and 3%), this finding put in question the commonly held
belief of the inevitably adverse course of metastatic bre-
ast cancer16,17. In this report anthracycline-based chemo-
therapy is used as first-line treatment what is nowadays
beside taxane-based combination chemotherapy consid-
ered as the main chemotherapy backbone for HER2-neg-
ative metastatic breast cancer. In chemotherapy treat-
ment of women with metastatic breast cancer, the most
effective is first-line chemotherapy, while the efficacy of
second and subsequent lines is uniformly poor18. In work
done by Greenberg et al, six subgroups of patients with
pulmonary metastases as the only site of disease out of
total of 263 patients living in long-term complete remis-
sion were identified, who were treated with chemother-
apy and/or hormonotherapy. One of these six subgroups,
which involved 21 patients had the longest duration of
complete remission of even 231 months (more than 19
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years)16. This is very indicative, since our patient also
had a single site of disease – pulmonary metastases only.
The most common sites for breast cancer metastasis
include the bone, lung, liver, lymph nodes, chest wall,
and brain. However, case reports have documented bre-
ast cancer dissemination to almost every organ in the
body. In one large autopsy series the peritoneum was in-
volved in 25% cases19.
When discussing the aims of metastatic breast cancer
treatment, several aspects could be identified: the need
to prolong life, decrease tumor burden, reduce cancer-re-
lated symptoms and maintain of quality of life and func-
tion. In a metastatic setting, therapy is not generally con-
sidered curative. Numerous studies demonstrated that
patients who have received less anticancer therapy, have
a longer disease-free interval since initial diagnosis, soft
tissue or bone metastases, fewer symptoms and better
performance status, and tumors that are hormone-recep-
tor positive are likely to experience longer survival with
metastatic disease than more agressively treated pa-
tients (shorter intervals between treatments), visceral
metastases, and greater symptomatology20. Long-term
disease-free survivors are younger and healthier than
the overall patient population, have fewer sites of metas-
tasis, and smaller disease volumes. The largest analysis
of long-term responders found that 55% of long-term
complete responders had only one disease site, compared
with 29% of the total population: 66% of those in com-
plete remission for more than 5 years had lower tumor
burden in contrast with 24% in the general patient
population21.
Conclusion
Our patient in moment of dissemination had a low tu-
mor burden, was young, premenopausal, with no co-
morbidity, in excellent performance status and had a
long recurence-free period after primary treatment. All
listed factors indicated favourable outcome. It is wor-
thwile to identify such a metastatic breast cancer popula-
tion where treatment with curative intent can enable a
durable response. However, when disease finally relap-
ses, second and subsequent chemotherapy lines have no
effect and a poor outcome is foreseen.
Furthermore, regardless of breast cancer stage or no
previous history of cancer, new onset of dermatomyositis
is always suspicious for both occult cancer or cancer re-
currence no matter how long the remission endured and
clinical measure should be undertaken to adequately
stage and treat the patient.
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DERMATOMIOZITIS KAO PARANEOPLASTI^KI SINDROM PERITONEALNOG I OVARIJALNOG
RELAPSA NAKON DUGOG PERIODA POTPUNE REMISIJE U BOLESNICE S METASTATSKIM
BILATERALNIM RAKOM DOJKE
S A @ E T A K
Dermatomiozitis je rijetka bolest karakterizirana upalnim promjenama u mi{i}ima i karakteristi~nim ko`nim pro-
mjenama. Kada se pojavi u bolesnika s rakom, dermatomiozitis mo`e upu}ivati na povrat ili progresiju maligne bolesti
te ~esto ukazuje na lo{ ishod. U ovom radu opisali smo povezanost izme|u dermatomiozitisa i raka dojke, te raspravili
mogu}nosti lije~enja metastatskog raka dojke, kao i zna~ajke bolesnica koje smatramo izlije~enima – tzv. »long-term
survivors«. Prikazujemo slu~aj 57-godi{nje bolesnice s metastatskim bilateralnim karcinomom dojke u koje je pojava
paraneoplasti~kog dermatomiozitisa u podlozi razotkrila recidiv osnovne bolesti u jajnicima te po peritoneumu. Bo-
lesnica je prethodno imala 15 godina dugo razdoblje bez znakova bolesti po zavr{etku primarnog lije~enja, nakon ~ega je
nastupila plu}na diseminacija. Po provedenoj kemoterapiji baziranoj na antraciklinima nasupio je kompletan odgovor
(remisija) koja je trajala 15 godina, nakon ~ega je nastupila prethodno opisana diseminacija u podru~je jajnika te peri-
toneuma. Dermatomiozitis se povukao po uvo|enju druge linije kemoterapije bazirane na taksanima. Po kompletiranju
{est ciklusa kemoterapije gemcitabinom i paklitakselom, obrada je ukazala na daljnju progresiju bolesti. Bolesnica je
potom primila {est ciklusa tre}e linije kemoterapije po CAP protokolu (ciklofosfamid, doksorubicin, cisplatin), no bolest
je progredirala i zapo~eta je peroralna kemoterapija kapecitabinom. Bolesnica je primila ~etiri ciklusa terapije kapeci-
tabinom, nakon ~ega je nastupila daljnja opse`na progresija te je bolesnica kona~no preminula pod slikom masivne
plu}ne embolije. Ovaj slu~aj ukazuje na potrebu temeljitog „staginga“ i klini~ke obrade u slu~aju pojave dermatomiozi-
tisa u bolesnica s rakom dojke, bez obzira na prethodnu trajnu i stabilnu kompletnu remisiju. Nadalje, dr`imo da je u
mladih bolesnica s metastatskim rakom dojke koje su dobrog op}eg stanja i nemaju komorbiditeta potrebno lije~enje s
kurativnom namjerom, jer je mogu}e da se takvim lije~enjem postigne dugotrajna kompletna remisija. Ipak, ako kona-
~no do|e do povrata bolesti (relapsa), o~ekuje se lo{ ishod.
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